Impact of cinacalcet introduction on MBD management: The MBD-5D study in Japan

Kidney International Supplements

Volumn 3, Issue 5, 2013, Pages 436-441

  Fukuma, Shingo ^a,b,c   Kurita, Noriaki ^a,c   Fukagawa, Masafumi ^d   Akizawa, Tadao ^e   Fukuhara, Shunichi ^a,f  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c Institute for Health Outcomes and Process Evaluation Research   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^f FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cinacalcet; Dialysis patients; Mineral and bone disorder

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR ACTIVATOR;

BONE DISEASE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; FRACTURE; HEMODIALYSIS PATIENT; HUMAN; JAPAN; MINERAL AND BONE DISORDER; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 84896720785     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2013.91     Document Type: Review

References (10)

1. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
2. Investigators ET, Chertow GM, Block GA et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494.
3. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
4. Fukuhara S, Akizawa T, Fukagawa M et al. Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients: rationale and study design. Ther Apher Dial 2011; 15: 169-175.
5. Yokoyama K, Fukuhara S, Fukagawa M et al. Results of the survey on practice patterns including MBD management at dialysis facilities: as part of the MBD-5D. J Jpn Soc Dial Ther 2011; 44: 557-566 (Japanese).
6. Bradbury BD, Brookhart MA, Winkelmayer WC et al. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis 2009; 54: 554-560.
7. Fukagawa M, Fukuma S, Onishi Y et al. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol 2012; 7: 1473-1480.
8. Fukagawa M, Komaba H, Onishi Y et al. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. Am J Nephrol 2011; 33: 427-437.
9. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
10. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-972.